Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Clinical Trials
•
Pediatric Oncology
•
Oncology
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
Related Questions
What is your approach to patients/parents seeking alternative or complementary treatment in pediatric oncology patients?
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
What is the recommended fungal workup in an immunocompromised patient after 5 days of persistent fever?
Do you use prophylactic defibrotide in pediatric patients undergoing BMT who are considered to be at high risk for the development of VOD/SOS?
For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?
Do you routinely use thrombopoietin receptor agonists (like romiplostim) to address chemotherapy-induced thrombocytopenia in solid tumor pediatric oncology patients?
How would you approach the prevention of irinotecan-induced diarrhea in a patient who previously experienced a diffuse rash with cefixime?
If a pediatric patient has a prior history of cancer-associated thrombosis while receiving active treatment, can they be on estrogen-containing OCPs in the future?
When do you consider altering treatment for a patient with metastatic osteosarcoma who showed poor response to upfront therapy with MAP (doxorubicin, cisplatin, methotrexate) chemotherapy?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
